The CEO of Novavax Inc. said the company’s COVID-19 vaccine could be a good booster option for people who have received other immunizations, as the drugmaker seeks to increase production and gain approvals across the world. world.
“Our vaccine is ideal as a booster”Said the executive director on Monday, Stanley Erck, in an interview with Bloomberg Television.
Erck noted that the Gaithersburg, Maryland-based company has solved the manufacturing problems that delayed its vaccine this year, so it hopes to be able to produce 150 million doses a month with its partner Serum Institute of India in December.
Novavax was one of the first pharmaceutical companies to receive support from the Government of USA to accelerate the development of COVID vaccines.
However, the company lagged behind its rivals in the race to its local market and has increasingly focused on obtaining authorizations abroad. In recent days, he requested authorizations in United Kingdom, Australia and Canada.
Erck He said he expects COVID infections to increase without booster shots, and that his product could be a good complementary option for people who have received immunizations from other companies.
Recently, a study by the National Institutes of Health (NIH) showed a potential benefit of the so-called combination of vaccines, which is why US regulators approved the strategy for some of the Americans to receive one of the three currently licensed vaccines.
Novavax said it expects to complete the submission of a regulatory package to US regulators by the end of the year.
.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
